Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19

Martins Tomazini, Bruno; Silva Maia, Israel; Biasi Cavalcanti, Alexandre; Berwanger, Otávio; Goulart Rosa, Régis; Cordeiro Veiga, Viviane; Avezum, Álvaro; D. Lópes, Renato; Regina Bueno, Flávia; Vitoria A. O. Silva, Maria; Pellison Baldassare, Franca; Leite Vieira Costa, Eduardo; Antonio Bonifácio Moura, Ricardo; Ouriques Honorato, Michele; Nathan Costa, André; Petri Damiani, Lucas; Lisboa, Thiago; Kawano-Dourado, Letícia; G. Zampieri, Fernando; Benfatti Olivato, Guilherme; Righy, Cássia; Prata Amêndola, Cristina; Muriel Longo Roepke, Roberta; Helena Machado Freitas, Daniela; Neves Forte, Daniel; Geraldo Rezende Freitas, Flávio; César Ferreira Fernandes, Caio; Maria Garcia Melro, Lívia; S. Gedealvares, F.; Costa Morais, Douglas; Zung, Stevin; Machado, F.S.; César Pontes Azevedo, Luciano; COVID-19 Brazil III Investigators, COALITION

doi:10.1001/jama.2020.17021

Public

Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19

Published in JAMA • Sep 2, 2020

Authors:

Bruno Martins Tomazini

Israel Silva Maia

Alexandre Biasi Cavalcanti

Abstract

Importance: Acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19) is associated with substantial mortality and use of health care resources. Dexamethasone use might attenuate lung injury in these patients. Objective: To determine whether intravenous dexamethasone incr...

Subject

Medicine

ARDS

Dexamethasone

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!